Search This Blog

Wednesday, November 18, 2026

Teva IGALMI OKd as First At-Home Acute Treatment for Agitation of Schizophrenia, Bipolar

 

First at-home treatment provides a new option for patients and caregivers to address agitation outside of a healthcare setting

Approval is supported by results of the Phase 3 SERENITY Trial, in which IGALMI met its primary endpoint of safety and tolerability in the at-home setting

Milestone supports Teva’s Pivot to Growth strategy and adds to company’s commitment to patient-centered innovation in neuroscience

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the U.S. Food and Drug Administration (FDA) approval of IGALMI (dexmedetomidine) sublingual film for at-home use. With this approval, IGALMI becomes the first FDA-approved treatment that can be used at home for agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults.

Agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder affects between 25% and 40% of patients across these conditions.2 Acute agitation can escalate quickly, creating significant challenges for patients, families and caregivers and, in up to 21% of cases, can result in an emergency department visit or hospitalization.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.